DCC3246 |
Mbt-fh Inhibitor-7 |
The first selective small molecule inhibitor of the Mycobacterium tuberculosis fumarate hydratase |
|
DCC3247 |
Mbx-1066 |
Potent antibacterial agent against a wide range of Gram-positive and Gram-negative bacteria |
|
DCC3248 |
Mbx-1162 |
Novel antibacterial agent, remarkably potent against antibiotic-resistant bacterial strains such as MDR A. baumannii , ESBL-producing Klebsiella pneumoniae, VRE, and MRSA |
|
DCC3249 |
Mbx-1887 |
Antibacterial agent, with a relatively narrow spectrum against bacteria and a very high CC 50 value |
|
DCC3250 |
Mbx2546 |
Novel specific inhibitor of HA-mediated viral entry, inhibiting HPAI H5N1 virus strain A/Hong Kong/H5N1 |
|
DCC3251 |
Mc1220 |
Topical nonnucleoside reverse transcriptase inhibitor, partially preventing vaginal RT-SHIV infection of macaques |
|
DCC3252 |
Mc-1353 |
Potent and HDAC class I-selective inhibitor |
|
DCC3253 |
Mc1420 |
Novel potent acetylcholinesterase (AChE) inhibitor |
|
DCC3254 |
Mc-1-f2 |
The first inhibitor of forkhead Box Protein C2 (FOXC2) |
|
DCC3255 |
Mc2050 |
Novel selective PARP1 inhibitor, inhibitng apoptosis and blocking poly ADP-ribosylation of histone H1 in hydrogen peroxide treated SH-SY5Y neuroblastoma cells |
|
DCC3256 |
Mc2392 |
Novel hybrid retinoid-HDAC inhibitor |
|
DCC3257 |
Mc-70 Hydrochloride |
Potent P-gp inhibitor with good selectivity towards BCRP pump (EC50 values 0.05 μM, 0.69 μM, 9.3 μM, and 73 μM for Caco-2, MDR1, MRP1, and BCRP inhibition, respectively) |
|
DCC3258 |
Mca-13 |
Novel neurotropic agent |
|
DCC3259 |
Mca-yvadapk(dnp)-oh |
Specific and highly fluorescent substrate for caspase-1, also acting as a substrate for caspase-4 |
|
DCC3260 |
Mcc1019 |
Novel selective inhibitor of the Polo-box domain of Polo-like kinase 1 (PLK1) |
|
DCC3261 |
Mcc1189 |
First-in-class inhibitor of MFS efflux pump CaMdr1p |
|
DCC3262 |
Mcc-134 |
Novel inverse agonist for the pancreatic-type ATP-sensitive K channel as vascular relaxing agent |
|
DCC3263 |
MCC950 free acid
Featured
|
Potent and selective inhibitor of NLRP3, reducing interleukin-1β (IL-1β) production in vivo and attenuating the severity of experimental autoimmune encephalomyelitis (EAE) |
|
DCC3264 |
Mc-doxhzn |
Albumin-binding prodrug of Doxorubicin |
|
DCC3265 |
Mcg315 |
Novel potent F508del-CFTR corrector, modulating poly-ADP ribose polymerase 3 and poly-ADP ribose polymerase 16 activities |
|
DCC3266 |
Mci-225 |
Selective NA reuptake inhibitor with 5-HT3 receptor antagonism |
|
DCC3267 |
Mcl0527-3 |
Novel inhibitor of p53-MDM2 interaction |
|
DCC3268 |
Mcl-1 Degrader C3 |
Novel potent and selective degrader of Mcl-1 |
|
DCC3269 |
Mcl-1 Inhibitor-11 |
Novel reversible covalent inhibitor for Mcl-1 with improved water solubility than Mcl-1 Inhibitor-5 |
|
DCC3270 |
Mcl-1 Inhibitor-39 |
Novel selective Mcl-1 inhibitor |
|
DCC3271 |
Mcl-1 Inhibitor-5 |
The first reversible covalent inhibitor for Mcl-1, a protein-protein interaction (PPI) target |
|
DCC3272 |
Mcl1-in-1 |
Novel potent and selective inhibitor of the apoptosis regulating proteins Mcl-1 |
|
DCC3273 |
Mcmmad
Featured
|
Novel mc (maleimidocaproyl) linker plus MMAD (Monomethylauristatin D) to be used for prepare antibodies conjugates via cysteine-capped mechanism |
|
DCC3274 |
Mct4-in-18n |
Novel highly selective inhibitor of monocarboxylate transporter 4 (MCT4/SLC16A3), resulting in lactate efflux inhibition and reduction of cellular viability in MCT4 high expressing cells |
|
DCC3275 |
Mcule-5948770040 |
Novel SARS-CoV-2 Main Protease (Mpro) inhibitor, binding to Subsites S1 and S2 (Kd=1.3 µM) |
|